I agree that this site is using cookies. You can find further informations here.
X
Blumenberg, V
94  results:
Search for persons X
?
1

Modification of Lugano Criteria by Pre‐Infusion Tumor Kinet..:

Kunz, W. G. ; Blumenberg, V. ; Rejeski, K....
Hematological Oncology.  41 (2023)  S2 - p. 347-348 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Reasons for Discordance Among Imaging‐based Response Criter..:

Winkelmann, M. ; Blumenberg, V. ; Rejeski, K....
Hematological Oncology.  41 (2023)  S2 - p. 529-530 , 2023
Link: https://doi.org/10.1002/..
 
?
3

SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELA..:

Rejeski, K. ; Perez, A. ; Iacoboni, G....
Hematological Oncology.  41 (2023)  S2 - p. 204-204 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR ..:

Blumenberg, V. ; Siegmund, L. ; Frölich, L....
HemaSphere.  6 (2022)  - p. 1328-1329 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K. ; Albanyan, O. ; Iacoboni, G....
HemaSphere.  6 (2022)  - p. 1340-1341 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER..:

Rejeski, K. ; Blumenberg, V. ; Hildebrand, F....
HemaSphere.  6 (2022)  - p. 1321-1322 , 2022
Link: https://doi.org/10.1097/..
 
?
7

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION ..:

Frölich, L. ; Blumenberg, V. ; Rejeski, K....
HemaSphere.  6 (2022)  - p. 2080-2081 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSE..:

Bücklein, V. ; Perez, A. ; Iacoboni, G....
HemaSphere.  6 (2022)  - p. 1330-1331 , 2022
Link: https://doi.org/10.1097/..
 
?
9

CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATE..:

Rejeski, K. ; Perez, A. ; Sesques, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐F..:

Bücklein, V. ; Blumenberg, V. ; Ackermann, J....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
11

Arming T cells with C-X-C-motive receptor 6 enables adoptiv..:

Lesch, S. ; Blumenberg, V. ; Stoiber, S....
European Journal of Cancer.  110 (2019)  - p. S25-S26 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Inferior outcomes of EU versus US patients treated with CD1..:

Bücklein, V ; Perez, A ; Rejeski, K...
http://edoc.mdc-berlin.de/23596/1/23596oa.pdf.  , 2023
Link: http://edoc.mdc-berlin.d..
 
?
13

Severe hematotoxicity after CD19 CAR-T therapy is associate..:

Rejeski, K ; Perez, A ; Iacoboni, G...
http://edoc.mdc-berlin.de/23746/1/23746oa.pdf.  , 2023
Link: http://edoc.mdc-berlin.d..
 
?
14

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K ; Albanyan, O ; Iacoboni, G...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429233/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

The CAR-HEMATOTOX risk-stratifies patients for severe infec..:

Rejeski, K ; Perez, A ; Iacoboni, G...
http://edoc.mdc-berlin.de/21645/1/21645oa.pdf.  , 2022
Link: http://edoc.mdc-berlin.d..
 
1-15